The liver cancer secondary treatment stays valid, in fact, if...

The liver cancer secondary treatment stays valid, in fact, if you read the ASX market announcement, the SRX website and everything else written on SRX 2day, the results are quite good without the primary treatment. It is true that the colorectal primary treatment fails, for now, which dampens credibility in a stock like SRX that has been trading on a blue sky basis since about $28. A colorectal cancer cure would have put SRX above Cochlear or any other imaginable treatment of an ASX based company, it would have impacted NASDAQ in info flow, it was a bit too good to be true at this early point and would have knocked SRX to the stratosphere. $39 was arguably too light if the market thought colorectal cancer treatment was a serious probability of success, can u imagine what US biopharma coy's would have done if the clinical trials were a success?

The liver cancer treatment, with the chemo, succeeds, it is for this reason that those of us bought below $28 originally b4 UBS and the acolytes of UBS got involved in it. Those r the ones that have been selling below $19 or generating a conditional trade a.ka. using a stop loss.Although it is no longer a free carry for me due to the units bought 2day, SRX will make quite a recovery depending on how strong the governance remains.

The volume didn't really go up 2day to higher volumes than when it reached $28, suggested long time holders r staying put, the LT holder is judging management credibility not really a concern. This might change if there r no other surprises.